Canopy Growth (CGC)
(Delayed Data from NSDQ)
$4.86 USD
+0.27 (5.88%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $4.86 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.86 USD
+0.27 (5.88%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $4.86 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
Canopy Growth Corporation (CGC) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Canopy Growth (CGC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Canopy Growth Corporation (CGC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth (CGC) delivered earnings and revenue surprises of 15.15% and 2.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
by Moumi Mondal
Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.
Canopy Growth Corporation (CGC) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $9.18, denoting a +0.77% change from the preceding trading day.
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Canopy Growth (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 0.69% and 1.80%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Canopy Growth Corporation (CGC) concluded the recent trading session at $10.85, signifying a -1.36% move from its prior day's close.
Investors Heavily Search Canopy Growth Corporation (CGC): Here is What You Need to Know
by Zacks Equity Research
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Strength Seen in Canopy Growth (CGC): Can Its 11.0% Jump Turn into More Strength?
by Zacks Equity Research
Canopy Growth (CGC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Canopy Growth Corporation (CGC) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Canopy Growth Corporation (CGC) settling at $10.24, representing a -0.97% change from its previous close.
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Do Options Traders Know Something About Canopy Growth (CGC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Canopy Growth Corporation (CGC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $4.79, moving -0.83% from the previous trading session.
ResMed (RMD) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 3.87% and 0.46%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) reachead $4.41 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Canopy Growth Corporation (CGC) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Canopy Growth Corporation (CGC) closed at $4.56, indicating a -0.87% shift from the previous trading day.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw Canopy Growth Corporation (CGC) settling at $4.86, representing a +1.46% change from its previous close.
Zacks Market Edge Highlights: Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals
by Zacks Equity Research
Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals are part of the Zacks Market Edge blog.
Pot Stocks: Values or Traps?
by Tracey Ryniec
Pot stocks used to be hot but many have plunged over the last 2 years. Are there deals?
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.
Here's Why Canopy Growth Corporation (CGC) Fell More Than Broader Market
by Zacks Equity Research
In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $0.51, denoting a -1.03% change from the preceding trading day.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and latest launches.